Leukemia Clinical Trials in Atlanta

Showing 1101-1120 of 1,466 trials

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

NCT00009620

This large randomized trial tested whether phenobarbital given to a pregnant woman about to deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to 32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were randomized to phenobarbital or usual care. They were treated until they deliver or the fetus reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos corrected age for neurodevelopmental outcome.

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+2 more

NICHD Neonatal Research Network610 participantsStarted Feb 1993

Palo Alto, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

COMPLETED< 1 mile

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

NCT01203423

This study was an observational study to estimate the prevalence of Persistent pulmonary hypertension of the newborn (PPHN) among term or near-term infants with severe respiratory disease.

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+3 more

NICHD Neonatal Research Network385 participantsStarted Oct 1993

Palo Alto, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +10 more locations

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Leukemia Trials in Other Cities

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Other Conditions in Atlanta